EFFECT OF DOXORUBICIN ON LIPID PROFILE IN ALBINO RATS

Abstract

Abstract Doxorubicin is widely used anthracycline drug used in cancer chemotherapy and it acts by inhibiting the enzyme topoisomerase II. One of its major side effects is that it induces cardiomyopathy and hence it is used experimentally to induce animal model of cardiomyopathy. This work evaluated the effect of doxorubicin administration on lipid profile. Albino rats were randomly divided into three(3) groups. Group I served as control group (non-treated), group II and III were administered with doxorubicin 1.0 mg/kg and 2.0mg/kg respectively for two weeks. Standard analytical procedures were used for biochemical analysis. Results showed that treatment with doxorubicin significantly (p<0.05) increases total cholesterol, triglycerides, low density lipoprotein cholesterol (VLDL-C) and anthrogenic index of plasma. The drug also caused significant (P<0.05) decrease in the levels of high density lipoprotein (HDL). The results indicated that treatment with doxorubicin is associated with dyslipidemia. .